The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Novel insights into the value of CTCs in myeloma and smoldering myeloma
In this interview, Jesús San Miguel, MD, PhD, University of Navarra, Pamplona, Spain, shares novel insights into the significance of circulating tumor cells (CTCs) in both smoldering and active multiple myeloma. He highlights that 73% of patients with smoldering myeloma have CTCs, which can be used as a tool to predict the risk of progression to active disease. Prof. San Miguel also notes that 10% of patients with active myeloma lack CTCs and discusses the value of measuring CTCs by blood flow to assess measurable residual disease (MRD). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
